245 related articles for article (PubMed ID: 33448035)
1. Nanoparticle-Mediated Delivery of Inhaled Immunotherapeutics for Treating Lung Metastasis.
Jin Q; Zhu W; Zhu J; Zhu J; Shen J; Liu Z; Yang Y; Chen Q
Adv Mater; 2021 Feb; 33(7):e2007557. PubMed ID: 33448035
[TBL] [Abstract][Full Text] [Related]
2. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
3. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
[TBL] [Abstract][Full Text] [Related]
4. Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
Li L; Miao Q; Meng F; Li B; Xue T; Fang T; Zhang Z; Zhang J; Ye X; Kang Y; Zhang X; Chen Q; Liang X; Chen H; Zhang X
Theranostics; 2021; 11(12):6033-6043. PubMed ID: 33897897
[TBL] [Abstract][Full Text] [Related]
5. Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.
Kell SA; Kachura MA; Renn A; Traquina P; Coffman RL; Campbell JD
Int Immunopharmacol; 2019 Jan; 66():296-308. PubMed ID: 30502651
[TBL] [Abstract][Full Text] [Related]
6. Aerosolized immunotherapeutic nanoparticle inhalation potentiates PD-L1 blockade for locally advanced lung cancer.
Liu Y; Crowe WN; Wang L; Petty WJ; Habib AA; Zhao D
Nano Res; 2023 Apr; 16(4):5300-5310. PubMed ID: 37228440
[TBL] [Abstract][Full Text] [Related]
7. cGAS-STING, an important pathway in cancer immunotherapy.
Jiang M; Chen P; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; Ye L; He Y; Zhou C
J Hematol Oncol; 2020 Jun; 13(1):81. PubMed ID: 32571374
[TBL] [Abstract][Full Text] [Related]
8. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
9. Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy.
Kalim M; Iqbal Khan MS; Zhan J
Chem Biol Drug Des; 2020 Jun; 95(6):552-566. PubMed ID: 32166894
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
[TBL] [Abstract][Full Text] [Related]
11. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
Lee SH; Lee HT; Lim H; Kim Y; Park UB; Heo YS
Biochem Biophys Res Commun; 2020 Jun; 527(1):226-231. PubMed ID: 32446372
[TBL] [Abstract][Full Text] [Related]
14. Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer.
Zhou L; Xu Q; Huang L; Jin J; Zuo X; Zhang Q; Ye L; Zhu S; Zhan P; Ren J; Lv T; Song Y
Cancer Lett; 2021 Mar; 500():163-171. PubMed ID: 33278498
[TBL] [Abstract][Full Text] [Related]
15. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
16. Biomineralized MnO
Deng Z; Xi M; Zhang C; Wu X; Li Q; Wang C; Fang H; Sun G; Zhang Y; Yang G; Liu Z
ACS Nano; 2023 Mar; 17(5):4495-4506. PubMed ID: 36848115
[TBL] [Abstract][Full Text] [Related]
17. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8
Chen J; Song Y; Miao F; Chen G; Zhu Y; Wu N; Pang L; Chen Z; Chen X
Cancer Sci; 2021 Sep; 112(9):3437-3454. PubMed ID: 34152672
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel in chitosan-based nanocapsules conjugated with an anti-Tn antigen mouse/human chimeric antibody as a promising targeting strategy of lung tumors.
Castro A; Berois N; Malanga A; Ortega C; Oppezzo P; Pristch O; Mombrú AW; Osinaga E; Pardo H
Int J Biol Macromol; 2021 Jul; 182():806-814. PubMed ID: 33857513
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
20. Targeting macrophage priming by polyphyllin VII triggers anti-tumor immunity via STING-governed cytotoxic T-cell infiltration in lung cancer.
Yu J; Deng H; Xu Z
Sci Rep; 2020 Dec; 10(1):21360. PubMed ID: 33288772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
